Meeting
2022 ASCO Annual Meeting
Therapy related myeloid neoplasms (t-MNs) following PARP inhibitors (PARPi): Real-life experience.
Authors
Vincent Marmouset
Gustave Roussy, Villejuif, France
Vincent Marmouset , Justine Decroocq , Sylvain Garciaz , Gabriel Etienne , Amine Belhabri , Lauris Gastaud , Sarah Bertoli , Celestine Simand , Madalina Uzunov , Sylvain Chantepie , Alexis Genthon , Celine Berthon , Edmond Chiche , Pierre-Yves Dumas , Felix Blanc-Durand , Patricia Pautier , Arnaud Pages , Christophe Marzac , Alexandra Leary , Jean Baptiste Micol
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Myelodysplastic Syndromes (MDS)
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 7057)
DOI
10.1200/JCO.2022.40.16_suppl.7057
Abstract #
7057
Poster Bd #
288
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).
First Author: June Evelyn Jeon
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects.
First Author: Elias Chandran
Poster
2023 ASCO Genitourinary Cancers Symposium
Clinical and molecular features of ATM and BRCA2 mutations in metastatic prostate cancer.
First Author: Xiaolei Shi
Poster
2022 ASCO Annual Meeting
Comprehensive whole-exome and transcriptome profiling to identify actionable alterations associated with response to PARP inhibitors in breast cancer.
First Author: Susan M. Dombrowski